When it comes to vaccines, people always have some questions. "Should I get vaccinated?"What exactly is the effect of the vaccine?"Is the safety of the vaccine guaranteed?At this time, there is a person who is trying to answer these questions with his practical actions, and he is the protagonist of this issue of "Cheer for You": Zheng Haifa, general manager of Beijing Minhai Biotechnology.
China's vaccines: benefiting the country and moving towards the international stage.
On December 11, 2023, Beijing Minhai Biotechnology Co., Ltd. reached a cooperation agreement with Egyptian vaccine companies, and the two parties jointly signed a 13-valent pneumococcal polysaccharide conjugate vaccine** and a technology licensing transfer agreement. The signing of this agreement marks a milestone for Chinese vaccine companies to go abroad again.
This is the world's first "dual-vector" 13-valent pneumococcal polysaccharide conjugate vaccine independently developed by China.
In 2006, Zheng Haifa led this research and development project. After a long, arduous and uncertain research and development process, in September 2021, the 13-valent pneumococcal polysaccharide conjugate vaccine was successfully launched, which lasted 15 years. Compared with the previous similar vaccines, the time limit for vaccination is much relaxed. ** Nearly half as cheap as vaccines from foreign companies. According to clinical trials, this vaccine has a good safety profile, a low adverse reaction rate, and can be administered to infants and children aged six weeks to five years, which greatly relaxes the time limit for vaccination compared with previous similar vaccines.
Vaccine development is a work that requires passion and perseverance, and it requires practitioners to put it into practice with extremely high standards of depth accuracy. Therefore, even if a lot of time, money, personnel, and energy are spent, there is a possibility that they will fall short. Zheng Haifa and his team withstood the pressure of "giving up their efforts by the slightest difference" and accepted the test of every link and every level.
In the end, Zheng Haifa did it.
Pioneer of scientific research: work silently and live up to the heavy responsibility.
Zheng Haifa is a member of the National Pharmacopoeia Commission and regularly participates in the formulation and revision of national drug standards. In addition, he has two identities: as the general manager of the company, he needs to handle daily work such as R&D, quality, import and export, sales, finance, human resources, etcAs the chief scientist, he also needs to help others solve the "last mile" problem in scientific research.
This important figure in the field of vaccine research and development is a very down-to-earth person on weekdays. Zheng Haifa speaks with a local accent, and often smiles when he is interviewed, and he can't see a trace of anxiety caused by work.
Zheng Haifa told reporters that since he was a student, he has gradually become a studious person. He hopes that by learning knowledge, he can leave the countryside and see the bigger world. When he was a student, he gave almost all of his time to the library, "I should have been the one in my class who spent the longest time in the library." Zheng Haifa said. The library is like his "peach blossom paradise", and the vast amount of knowledge he has mastered invisibly has helped him grasp every opportunity to surpass himself.
After Zheng Haifa was admitted to the Graduate School of the Chinese Academy of Agricultural Sciences, he began to systematically study virology. Coming to Beijing, a hot land for realizing his ideals, Zheng Haifa worked harder to accumulate strength and waited for more opportunities to realize his self-worth.
In 1993, Zheng Haifa was transferred to the China Institute for the Control of Pharmaceutical and Biological Products, where he was exposed to the research and development of human vaccines and also undertook the work of vaccine approval. In addition, with the knowledge accumulated over the years of "drilling" the library, Zheng Haifa was able to quickly find out the content of the corresponding bibliography and find any mistakes when reviewing. "I'll find it out, list one, two, three, four (errors), supplement the information, and I'll look at it again. ”
In the past 10 years, Zheng Haifa's work ability has improved by leaps and bounds, but he does not want to continue to repeat himself. In 2004, Zheng Haifa chose to start a business.
Consistently: Vote for me with a peach, repay it with a plum.
Beijing has provided a broad platform for Zheng Haifa's "self-breakthrough". Zheng Haifa's first job was in Beijing, and after deciding to start his own business, he still chose to stay in Beijing. Zheng Haifa has devoted himself to Beijing, and the city of Beijing has also gifted him.
After devoting himself to scientific research, Beijing gave him and enterprises a lot of policy and scientific research funding support. "The decision to stay in Beijing was the right one. Zheng Haifa sighed.
Being in Beijing, a talent highland full of charm, vitality and innovation, Zheng Haifa also gave back. He has established a postdoctoral research station with the company, aiming to cultivate more scientific research talents in the field of vaccines.
Vaccine research and development is a tortuous, difficult and complicated undertaking, but Zheng Haifa uses "happiness" to describe his feelings about devoting himself to the vaccine cause. In Zheng Haifa's eyes, "it is a joy full of challenges".
Every vaccine is born and goes through a research and development process that is almost counted in ten years. In the future, there will be more vaccine practitioners like Zheng Haifa, who love this career and stick to their long and arduous posts to protect the long-term health of mankind.
At 21:40 on December 26, Beijing Satellite TV's "Cheer for You" column will take you into the world of Zheng Haifa and his vaccines.